Most Recent
Several lenders have appealed a ruling that found they failed to prove steel giant Arrium falsified representations on loan drawdown notices ahead of its $2.8 billion collapse, saying it was a “no brainer” that the company was in dire straits when its directors sought extra funds.
A former Greenwoods & Freehills partner will argue he is entitled to whistleblower protection in his lawsuit against the tax advisory firm and Lendlease, alleging he was forced to leave after refusing to put his name to a tax return and making protected disclosures.
The settlement figure in a class action against a unit of Suncorp Group has been revealed as $33 million, and super members are set to share in the net sum of $14 million, or 42.5 per cent of the deal.
Trading firm Epoch Capital has brought proceedings against a quantitative analyst who allegedly downloaded confidential information from the firm’s computers.
Norton Rose Fulbright has lost the co-head of its energy, infrastructure and resources team in Australia to King & Wood Mallesons, just months after the group's other leader jumped ship to another Big Six firm.
Korean drug company Samsung Bioepis has filed a second lawsuit seeking to invalidate German drug company Fresenius Kadi's patent for a biosimilar of blockbuster arthritis drug Humira.
The law firm that lost the first ever application for a group costs order in class actions against ANZ and Westpac has indicated it will revive its bid, tweaking a retainer agreement with group members in hopes of winning the court's approval this time.
Samsung Australia has been slapped with a $14 million penalty for running ads that misrepresented that its Galaxy smartphones could be used in pool and sea water.
The Scotch Whisky Association has sued an Australian food and drink importer for “flagrant” copyright infringement after it allegedly sold regular whisky with the trade organisation’s 'scotch whisky' certification trade mark.
A class action alleging the federal government contaminated Indigenous land with toxic firefighting foam has lost a challenge to a report by a scientist who declined to find that the foam could cause adverse health effects including immunosuppression and interfere with the efficacy of vaccines.